For millions of Americans living with kidney failure, managing heart rhythm problems like atrial fibrillation (AFib) is a daily challenge. Now, new research presented at a major medical conference suggests that a newer blood thinner called apixaban (brand name Eliquis) may be just as safe and effective as the older drug warfarin (Coumadin) for a specific group of dialysis patients.

This finding is important because people with kidney failure face extremely high risks of both dangerous blood clots and serious bleeding. The study focused on patients receiving peritoneal dialysis (PD), a type of home dialysis that uses the lining of the abdomen to filter waste from the blood. These patients differ in key ways from those who get traditional hemodialysis at a clinic.

What the Study Found

Researchers led by Dr. Mingyue He at Baylor College of Medicine in Houston analyzed real-world data from 660 patients with kidney failure and newly diagnosed AFib who were starting blood thinner treatment. All patients were on peritoneal dialysis. Half received apixaban and half received warfarin.

The study, presented at the National Kidney Foundation’s Spring Clinical Meetings, tracked five measures of how well the drugs worked:

• Ischemic stroke (stroke caused by a blood clot)
• Heart attack (myocardial infarction)
• Systemic thromboembolism (a clot that travels elsewhere in the body)
• Cardiovascular death
• A combined measure of all heart-related problems

In both the main analysis and a secondary analysis that accounted for patients who stopped treatment, the risks were similar between the two groups. The same was true for five safety outcomes:

• Intracranial bleeding (bleeding inside the skull)
• Major bleeding (serious enough to require hospitalization or transfusion)
• Clinically important bleeding (any bleeding that needed medical attention)
• Any stroke or intracranial bleeding combined
• Death from any cause

“Given the elevated stroke risk in kidney failure and the challenges of maintaining therapeutic anticoagulation with warfarin, apixaban may represent a practical alternative where anticoagulation is pursued,” Dr. He said in her presentation.

Why This Matters for Patients

Atrial fibrillation affects roughly 0.5% to 2% of the general population. But among people with kidney failure, that number jumps dramatically to between 11% and 25%, according to Dr. He. This means one in four dialysis patients may develop this heart rhythm disorder, which significantly raises the risk of stroke.

For decades, warfarin was the only oral blood thinner available. While effective, it comes with major drawbacks. Patients taking warfarin must follow strict dietary restrictions, avoiding foods high in vitamin K like leafy greens. They also need regular blood tests to monitor their international normalized ratio (INR) level, which measures how long it takes blood to clot. Keeping INR in the right range can be especially difficult for dialysis patients, whose bodies process medications differently.

Apixaban, on the other hand, is easier to manage. It does not require dietary restrictions or routine blood monitoring. Patients take a fixed dose by mouth, usually twice a day. This simplicity can improve quality of life and reduce the burden on both patients and healthcare providers.

The Unique Challenges of Kidney Failure and AFib

Managing blood thinners in kidney failure patients is notoriously difficult. These patients face a double-edged sword: they are at increased risk for dangerous blood clots that can cause stroke, but they are also at increased risk for major bleeding events.

“Long-term anticoagulation remains challenging in this population,” Dr. He explained. “Patients with kidney failure on hemodialysis face both increased risk of thrombosis and increased risk of major bleeding. Additionally, the commonly used risk scores – such as HAS-BLED score and the CHA2DS2-VASc score – perform suboptimally in patients with kidney failure on dialysis, making the risk-benefit assessment quite challenging.”

These risk scores are standard tools doctors use to decide whether a patient with AFib should take a blood thinner. But they were developed based on studies that largely excluded kidney failure patients, so their accuracy is limited in this group.

Why Peritoneal Dialysis Patients Need Separate Study

Most research on blood thinners in dialysis patients has focused on those receiving hemodialysis, where blood is filtered through a machine at a clinic three times a week. Peritoneal dialysis patients, who perform dialysis at home every day, are different in several important ways.

Dr. He pointed to factors such as intradialytic heparin exposure – a blood thinner given during hemodialysis sessions to prevent clotting in the machine – and repeated vascular cannulation, where needles are inserted into blood vessels. These create different bleeding risks compared with peritoneal dialysis patients, who do not receive heparin during their treatments and do not need vascular access needles.

“PD-specific data remains limited, but the distinction is very important because hemodialysis patients and peritoneal dialysis patients differ in several clinically relevant ways,” she noted.

Because of these differences, findings from studies dominated by hemodialysis patients may not apply to those on peritoneal dialysis. Currently, no randomized controlled trials have directly compared apixaban and warfarin specifically in the PD population.

Study Details and Limitations

The researchers used the U.S. Renal Data System, a national database that tracks all Americans with kidney failure, to identify Medicare beneficiaries diagnosed with AFib between January 2014 and December 2019. Using a statistical technique called propensity-score matching, they compared 330 new users of apixaban with 330 new users of warfarin.

At the start of the study, the average patient was 68 years old. About 76% were white and 17% were Black. Patients had been on dialysis for an average of 4 years. Their median CHA2DS2-VASc score was 4, which indicates a high risk of stroke. About 20% were also taking P2Y12 antiplatelet drugs, and 5% had a history of clinically important bleeding.

Both groups started blood thinner treatment about 6 days after their AFib diagnosis. However, treatment duration was generally short, and notably shorter in the apixaban group (68 days) compared with the warfarin group (96 days). This early discontinuation is a limitation of the study, as it may affect the results.

To check for hidden factors that could skew the results, the researchers looked at two “control outcomes”: pneumonia and hip fracture. These conditions should not be affected by which blood thinner a patient takes. Finding no difference between the groups for these outcomes suggests that the results are not being driven by major hidden biases.

Still, Dr. He acknowledged that because this was an observational study, not a randomized controlled trial, “residual confounding cannot be entirely ruled out.” Other limitations included the modest sample size and the early treatment discontinuation.

What Experts Say About Blood Thinners in Kidney Disease

Prior research in patients without kidney disease has generally favored apixaban over warfarin for preventing stroke or systemic embolism, while showing less bleeding and lower mortality risk. A 2019 meta-analysis of patients with late-stage chronic kidney disease also suggested apixaban was superior in reducing adverse outcomes.

However, experts caution that kidney failure patients are often excluded from the large randomized trials that set treatment guidelines. This leaves doctors with limited evidence when making decisions for this vulnerable population.

“Confirmation of these findings in PD-specific randomized trials is still needed,” Dr. He concluded.

Practical Takeaways for Patients and Caregivers

If you or a loved one has kidney failure and is on peritoneal dialysis, here is what this study means for you:

• Talk to your doctor about your options. Both apixaban and warfarin appear to have similar safety and effectiveness in PD patients with AFib, based on this real-world data.
• Consider the practical differences. Apixaban does not require dietary restrictions or regular blood tests, which may be more convenient for many patients.
• Understand your stroke risk. If you have AFib and kidney failure, your stroke risk is much higher than average. Blood thinners can significantly reduce this risk.
• Know the bleeding risks. All blood thinners increase the risk of bleeding. Your doctor will weigh this against the stroke prevention benefits.
• Do not stop or change medications without medical advice. Blood thinners are powerful drugs, and sudden changes can be dangerous.

This study provides important reassurance that apixaban is a reasonable option for peritoneal dialysis patients with AFib. But as with all medical decisions, the choice of blood thinner should be made individually, based on your specific health状况, preferences, and risk factors. More research, including randomized trials focused specifically on PD patients, will help clarify the best approach in the future.

Source: MedPage Today